INTECH BIOPHARM CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.15 TWD | -0.18% |
|
-0.18% | -9.20% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,524 | 1,481 | 2,085 | 2,326 | 3,889 | 4,109 |
| Enterprise Value (EV) 1 | 2,298 | 2,133 | 2,962 | 3,143 | 4,923 | 4,946 |
| P/E ratio | -6.66 x | -4.82 x | -8.28 x | -6.73 x | -11.8 x | -10.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 88.4 x | 88.8 x | 98.8 x | 59.8 x | 164 x | 159 x |
| EV / Revenue | 133 x | 128 x | 140 x | 80.8 x | 208 x | 191 x |
| EV / EBITDA | -11.1 x | -9.42 x | -18.9 x | -15 x | -21.1 x | -21 x |
| EV / FCF | -6.53 x | -13.2 x | -21.5 x | -22.9 x | -45.4 x | -33 x |
| FCF Yield | -15.3% | -7.55% | -4.65% | -4.36% | -2.2% | -3.03% |
| Price to Book | 1.02 x | 1.18 x | 1.57 x | 1.74 x | 3.77 x | 3.52 x |
| Nbr of stocks (in thousands) | 80,000 | 80,494 | 1,00,744 | 1,16,279 | 1,16,957 | 1,37,409 |
| Reference price 2 | 19.05 | 18.40 | 20.70 | 20.00 | 33.25 | 29.90 |
| Announcement Date | 27/03/19 | 30/03/20 | 26/03/21 | 28/03/22 | 29/03/23 | 13/03/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 17.23 | 16.68 | 21.11 | 38.9 | 23.65 | 25.85 |
| EBITDA 1 | -207.2 | -226.4 | -156.7 | -209.4 | -232.8 | -235.7 |
| EBIT 1 | -231 | -299.7 | -240.6 | -294 | -318.1 | -320.5 |
| Operating Margin | -1,340.1% | -1,796.37% | -1,139.78% | -755.76% | -1,345.12% | -1,239.87% |
| Earnings before Tax (EBT) 1 | -224.5 | -311.4 | -250.4 | -301.8 | -327.9 | -338 |
| Net income 1 | -222.1 | -311.4 | -250.4 | -301.8 | -327.9 | -338 |
| Net margin | -1,288.59% | -1,866.6% | -1,186.25% | -775.74% | -1,386.55% | -1,307.64% |
| EPS 2 | -2.860 | -3.820 | -2.500 | -2.970 | -2.823 | -2.810 |
| Free Cash Flow 1 | -351.8 | -161 | -137.8 | -137.2 | -108.4 | -150.1 |
| FCF margin | -2,041.39% | -965.16% | -652.74% | -352.6% | -458.21% | -580.7% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 27/03/19 | 30/03/20 | 26/03/21 | 28/03/22 | 29/03/23 | 13/03/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 774 | 652 | 876 | 817 | 1,034 | 837 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -3.738 x | -2.879 x | -5.594 x | -3.902 x | -4.441 x | -3.552 x |
| Free Cash Flow 1 | -352 | -161 | -138 | -137 | -108 | -150 |
| ROE (net income / shareholders' equity) | -15.6% | -20.4% | -17.3% | -22.6% | -27.7% | -30.7% |
| ROA (Net income/ Total Assets) | -6.07% | -7.32% | -5.75% | -7.04% | -7.72% | -7.61% |
| Assets 1 | 3,658 | 4,255 | 4,352 | 4,289 | 4,249 | 4,439 |
| Book Value Per Share 2 | 18.60 | 15.60 | 13.20 | 11.50 | 8.820 | 8.500 |
| Cash Flow per Share 2 | 1.600 | 1.710 | 2.030 | 1.900 | 0.5500 | 0.5700 |
| Capex 1 | 204 | 51.3 | 48.2 | 21.3 | 10.7 | 30 |
| Capex / Sales | 1,183.82% | 307.48% | 228.18% | 54.77% | 45.43% | 116.2% |
| Announcement Date | 27/03/19 | 30/03/20 | 26/03/21 | 28/03/22 | 29/03/23 | 13/03/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -9.20% | 115M | |
| +9.85% | 72.5B | |
| +13.69% | 9.11B | |
| -12.85% | 5.07B | |
| +60.16% | 5.01B | |
| +1.60% | 3.85B | |
| -19.20% | 2.46B | |
| +18.65% | 2.44B | |
| +24.62% | 2.27B | |
| -27.46% | 2.26B |
- Stock Market
- Equities
- 6461 Stock
- Financials Intech Biopharm Corporation